Panavance Therapeutics Announces Acceptance of Abstract to be Presented at the…
<!-- Name:DistributionId Value:8791270 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Panavance Therapeutics Inc.
Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology…
BERWYN, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel…
Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the…
BERWYN, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel…
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data…
Combination therapy of GP-2250 and gemcitabine proved to be effective for the treatment of pancreatic neuroendocrine tumors in vitro and in vivo, without the development of secondary…